{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:22:12Z","timestamp":1791235332173,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.coi.2025.102610","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T11:20:02Z","timestamp":1754479202000},"page":"102610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Can we cure antiphospholipid syndrome?"],"prefix":"10.1016","volume":"96","author":[{"given":"Pier Luigi","family":"Meroni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tedesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102610_sbref1","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102610_bib2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41584-018-0032-6","article-title":"Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?","volume":"14","author":"Meroni","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2025.102610_sbref3","doi-asserted-by":"crossref","first-page":"SI4","DOI":"10.1093\/rheumatology\/kead603","article-title":"Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones?","volume":"63","author":"Raschi","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102610_bib4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102610_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052588","article-title":"Understanding the pathophysiology of thrombotic APS through Animal Models","volume":"22","author":"Gandhi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2025.102610_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/ard.2005.045443","article-title":"Infectious origin of the antiphospholipid syndrome","volume":"65","author":"Shoenfeld","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102610_bib7","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1074\/jbc.M110176200","article-title":"Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the antiphospholipid syndrome","volume":"277","author":"Guerin","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coi.2025.102610_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/humupd\/dml051","article-title":"Pathogenic role of anti-beta2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin","volume":"13","author":"Di Simone","year":"2007","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.coi.2025.102610_bib9","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2025.102610_bib10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1600-0897.1996.tb00011.x","article-title":"Aspirin-interleukin-3 interrelationships in patients with antiphospholipid syndrome","volume":"35","author":"Fishman","year":"1996","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.coi.2025.102610_bib11","doi-asserted-by":"crossref","first-page":"ITC49","DOI":"10.7326\/AITC202304180","article-title":"Periprocedural anticoagulation","volume":"176","author":"Parks","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coi.2025.102610_bib12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/14779072.2023.2184353","article-title":"Safety and efficacy of intracoronary thrombolytic agents during primary percutaneous coronary intervention for STEMI","volume":"21","author":"Kulick","year":"2023","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.coi.2025.102610_sbref13","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3324\/haematol.2022.281505","article-title":"Plasminogen activator-coated nanobubbles targeting cellbound \u03b22-glycoprotein I as a novel thrombus-specific thrombolytic strategy","volume":"108","author":"Macor","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.coi.2025.102610_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2016.07.003","article-title":"Prevention & treatment of obstetrical complications in APS: is hydroxychloroquine the Holy Grail we are looking for?","volume":"75","author":"Meroni","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102610_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","article-title":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases","volume":"23","author":"Rainsford","year":"2015","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.coi.2025.102610_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01388","article-title":"Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications","volume":"9","author":"Tedesco","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102610_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood-2015-09-672139","article-title":"Complement activation in antiphospholipid syndrome and its inhibition to prevent re-thrombosis after arterial surgery","volume":"127","author":"Meroni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102610_bib18","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1097\/TP.0b013e31818a68e2","article-title":"Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement","volume":"86","author":"Ferraresso","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.coi.2025.102610_sbref19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.coi.2025.102610_bib20","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/1529-0131(200112)44:12<2870::AID-ART475>3.0.CO;2-Y","article-title":"Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype","volume":"44","author":"Meroni","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102610_bib21","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1002\/art.11449","article-title":"Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model","volume":"48","author":"Ferrara","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102610_bib22","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1538-7836.2004.00896.x","article-title":"Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells","volume":"9","author":"Ferrara","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2025.102610_bib23","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/annrheumdis-2013-203622","article-title":"A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients","volume":"73","author":"Erkan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102610_bib24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2249.2003.02358.x","article-title":"Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation","volume":"135","author":"Fischetti","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coi.2025.102610_bib25","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1172\/JCI86957","article-title":"Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy","volume":"126","author":"Lefkou","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2025.102610_bib26","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1182\/blood-2011-02-339234","article-title":"First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss","volume":"117","author":"Bramham","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102610_bib27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jri.2007.02.007","article-title":"Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation","volume":"77","author":"Salmon","year":"2008","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.coi.2025.102610_sbref28","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.ard.2025.02.012","article-title":"Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial","volume":"84","author":"Branch","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102610_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103710","article-title":"Intravenous immunoglobulin as a therapy for autoimmune conditions","volume":"24","author":"Danieli","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2025.102610_bib30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/imr.13404","article-title":"Immunomodulatory and anti-inflammatory properties of immunoglobulin G antibodies","volume":"328","author":"Hematianlarki","year":"2024","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coi.2025.102610_bib31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102610_bib32","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/annrheumdis-2019-216367","article-title":"Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus","volume":"79","author":"Chatzidionysiou","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102610_bib33","volume":"81","author":"Bettiol","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102610_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010077","article-title":"Is there a future for anti-CD38 antibody therapy in systemic autoimmune diseases?","volume":"9","author":"Benfaremo","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.coi.2025.102610_bib35","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jaci.2022.08.003","article-title":"New insights in systemic lupus erythematosus: from regulatory T cells to CAR-T-cell strategies","volume":"150","author":"Doglio","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2025.102610_sbref36","article-title":"Cellular therapies in rheumatic and musculoskeletal diseases","volume":"10","author":"Franco-Fuquen","year":"2024","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.coi.2025.102610_bib37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1515\/mr-2023-0033","article-title":"The mTOR pathway in the antiphospholipid syndrome","volume":"3","author":"Ji","year":"2023","journal-title":"Med Rev"},{"key":"10.1016\/j.coi.2025.102610_bib38","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1073\/pnas.0903158107","article-title":"Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus","volume":"107","author":"Humrich","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coi.2025.102610_bib39","article-title":"Efficacy and safety of low-dose interleukin-2 therapy in systemic lupus erythematosus: a systematic review","volume":"17","author":"Akkur","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.coi.2025.102610_bib40","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1177\/096120339800700236","article-title":"A chemically defined, toleragen-based approach for targeting anti-beta2-glycoprotein I antibodies","volume":"7","author":"Iverson","year":"1998","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2025.102610_sbref41","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1016\/j.jtha.2023.07.016","article-title":"Structural analyses of \u03b22-glycoprotein I: is there a circular conformation?","volume":"21","author":"Kumar","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2025.102610_bib42","first-page":"1684","article-title":"Beta 2 glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome","volume":"21","author":"La Rosa","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2025.102610_bib43","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1182\/blood-2011-01-333617","article-title":"In vivo distribution of \u03b22 glycoprotein I under various pathophysiologic conditions","volume":"118","author":"Agostinis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102610_bib44","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1191\/0961203306lu2315oa","article-title":"A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice","volume":"15","author":"Ostertag","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2025.102610_bib45","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/aji.12130","article-title":"Antiphospholipid antibodies affect human endometrial angiogenesis: protective effect of a synthetic peptide (TIFI) mimicking the phospholipid binding site of \u03b2(2) glycoprotein I","volume":"70","author":"Di Simone","year":"2013","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.coi.2025.102610_bib46","doi-asserted-by":"crossref","first-page":"J209","DOI":"10.1016\/j.jaut.2011.11.009","article-title":"Antiphospholipid induced murine fetal loss: novel protective effect of a peptide targeting the \u03b22 glycoprotein I phospholipid-binding site. Implications for human fetal loss","volume":"38","author":"de la Torre","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102610_bib47","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.4049\/jimmunol.160.11.5572","article-title":"Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies","volume":"160","author":"Del Papa","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2025.102610_bib48","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/ard.2004.021444","article-title":"Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro","volume":"64","author":"Di Simone","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102610_bib49","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1055\/s-0037-1603936","article-title":"Prevalence and thrombotic risk assessment of anti-\u03b22 glycoprotein I domain I antibodies: a systematic review","volume":"44","author":"Radin","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.coi.2025.102610_bib50","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2010.137281","article-title":"Anti-\u03b2\u2082-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4\/5: might it be the reason for their 'innocent' profile?","volume":"70","author":"Andreoli","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102610_bib51","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/art.39187","article-title":"Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against \u03b22 -glycoprotein i domain 1 and domain 4\/5: ratio of anti-domain 1 to anti-domain 4\/5 as a useful new biomarker for antiphospholipid syndrome","volume":"67","author":"Andreoli","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102610_bib52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaut.2018.02.002","article-title":"Beyond thrombosis: anti-\u03b22GPI domain 1 antibodies identify late pregnancy morbidity in antiphospholipid syndrome","volume":"90","author":"Chighizola","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102610_sbref53","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3324\/haematol.2018.198119","article-title":"New insight into antiphospholipid syndrome: antibodies to \u03b22glycoprotein I-domain 5 fail to induce thrombi in rats","volume":"104","author":"Durigutto","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.coi.2025.102610_bib54","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1182\/blood-2013-11-537704","article-title":"A non-complement-fixing antibody to \u03b22 glycoprotein I as a novel therapy for antiphospholipid syndrome","volume":"123","author":"Agostinis","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102610_sbref55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.842923","article-title":"PEGylated domain I of beta-2-glycoprotein I inhibits thrombosis in a chronic mouse model of the antiphospholipid syndrome","volume":"13","author":"Willis","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102610_bib56","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/art.41460","article-title":"Anti-neutrophil extracellular trap antibodies and impaired neutrophil extracellular trap degradation in antiphospholipid syndrome","volume":"72","author":"Zuo","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102610_bib57","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-020-00936-1","article-title":"NETs in APS: current knowledge and future perspectives","volume":"22","author":"Tambralli","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.coi.2025.102610_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00487","article-title":"Type I interferon signature in primary antiphospholipid syndrome: clinical and laboratory associations","volume":"10","author":"Palli","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102610_bib59","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2217\/imt-2020-0017","article-title":"Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations","volume":"12","author":"Anderson","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.coi.2025.102610_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/antib13010022","article-title":"Vitamin D status in patients with primary antiphospholipid syndrome (PAPS): a systematic review and meta-analysis","volume":"13","author":"Islam","year":"2024","journal-title":"Antibodies"},{"key":"10.1016\/j.coi.2025.102610_bib61","article-title":"Antiphospholipid syndrome and catastrophic antiphospholipid syndrome: a comprehensive review of pathogenesis, clinical features, and management strategies","volume":"16","author":"Parepalli","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.coi.2025.102610_bib62","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MBC.0000000000001313","article-title":"Efficacy and relative safety of caplacizumab in immune-mediated thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"35","author":"Peng","year":"2024","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.coi.2025.102610_bib63","doi-asserted-by":"crossref","first-page":"SI46","DOI":"10.1093\/rheumatology\/kead556","article-title":"What we know and what we don't know about catastrophic antiphospholipid syndrome","volume":"63","author":"Rodriguez-Pint\u00f3","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102610_bib64","article-title":"Case report: timing of eculizumab treatment in catastrophic antiphospholipid syndrome","volume":"10","author":"Carrara","year":"2024","journal-title":"Front Immunol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279152500086X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279152500086X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:41:23Z","timestamp":1772790083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095279152500086X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":64,"alternative-id":["S095279152500086X"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102610","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can we cure antiphospholipid syndrome?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102610","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102610"}}